TD Cowen raises Roivant Sciences stock price target on trial data

TD Cowen raised Roivant Sciences' price target to $55 from $50 and maintained a Buy rating after mosliciguat's Phase 2 PHocus trial exceeded expectations in pulmonary hypertension associated with interstitial lung disease. The drug delivered a 56% placebo-adjusted reduction in pulmonary vascular resistance and a 35.2-meter improvement in six-minute walk distance at week 16, versus expectations of roughly 32% and 20-32 meters, respectively. TD Cowen modeled $1.6 billion of peak fiscal-2035 sales for mosliciguat at a 65% probability of success, while Phase 3 initiation supports its commercial outlook.

Analysis

ROIV’s near-term setup is less about another analyst target increase and more about whether the market begins assigning material value to mosliciguat before pivotal data. The stock is already pressing its prior high, so a breakout can attract momentum and healthcare-specialist flows; however, the analyst’s risk-adjusted commercial framing implies a long-dated value driver rather than a 2026 earnings catalyst. At roughly $41.50, the path to $55 offers about 33% upside, but the valuation is increasingly exposed to any ambiguity in Phase 3 design, enrollment pace, or durability of functional benefit.

The relevant competitive read-through is to United Therapeutics (UTHR), whose Tyvaso franchise is the established PH-ILD standard. A differentiated oral, once-daily option could expand treatment penetration among patients reluctant or unable to use inhaled therapy, but it may initially be more complementary than disruptive; combination-use economics could enlarge the addressable market while limiting immediate UTHR share loss. Liquidia (LQDA) is a weaker direct read-through because its near-term value remains tied primarily to inhaled treprostinil execution rather than oral-mechanism substitution.

Consensus appears to be extrapolating a clean mid-stage signal into de-risked pivotal success. The contrarian issue is that hemodynamic improvement does not automatically translate into a commercially decisive functional, morbidity, or safety profile in a heterogeneous ILD population; a Phase 3 program can take 24-36 months to resolve this. The thesis is falsified sooner if management signals restrictive enrollment criteria, a materially larger trial than expected, elevated discontinuations, or cash deployment that reduces flexibility for pipeline acquisitions and buybacks.

Key Decisions for Investors

• Do not chase ROIV at the prior high; initiate a 50% tactical long only on a sustained close above $42.50 with a 1-3 month $50-$55 objective. Use a close below $38 as a risk-control level, which would indicate the post-data momentum bid has failed.
• For a 6-12 month position, prefer staged ROIV purchases on a 10-15% pullback rather than underwriting full pivotal success today. The upside case requires the market to capitalize mosliciguat as more than a single mid-stage asset; confirm this through disclosed Phase 3 timing, sample size, endpoint hierarchy, and enrollment guidance.
• Monitor UTHR for an overreaction: if it sells off materially on oral-competition fears without a change in Tyvaso prescription trends or management guidance, consider long UTHR versus ROIV. The likely initial market outcome is category expansion and combination use, not rapid incumbent displacement.
• Set an event alert around ROIV’s next earnings call for Phase 3 operational details and capital-allocation updates. A delayed start, unexpected trial complexity, or higher-than-expected cash burn should remove the tactical long setup regardless of continued bullish analyst revisions.